A biodrug developed by a Kerala researcher shows promise for cancer treatment.

Kerala researcher develop biodrug

Turmeric has long been praised for its medicinal properties.
Turmeric has long been praised for its medicinal benefits. Its cancer-curing qualities have long been known, and now a researcher from the capital city has demonstrated them once more. Dr Lekha Dinesh Kumar has combined two scientific technologies — RNA interference (RNAi) and nanotechnology — to create a biodrug that is non-toxic and biocompatible, as well as ensuring site-specific delivery of the same to targeted colon and breast malignant cells.
Curcumin, an active component of turmeric, has significant anticarcinogenic, anti-inflammatory, and antioxidant characteristics that make it excellent for cancer therapies, according to Dr Lekha, project head for cancer biology at the CSIR-Centre for Cellular & Molecular Biology (CCMB) in Hyderabad. The biodrug is transported by curcumin and other biological components.
The study, which was published in the peer-reviewed scientific journal ‘Nanoscale,’ was a cooperation between the CSIR-Centre for Cellular & Molecular Biology (CCMB) and the CSIR-National Chemical Laboratory (NCL). The RNAi method, often known as the ‘gene-silencing strategy,’ is applied in this case. RNAi is a promising approach for targeted and focused treatment of chronic diseases such as cancer.
This is paired with nanotechnology, resulting in the creation of nanocarriers that target RNA and silence it or silence the over-expressed gene. “It is the over-expressed gene that causes cell multiplication and, ultimately, tumour and malignant growth.” “The technology selectively turns down the gene,” explained Dr Lekha. The biggest barrier to the potential of RNAi-based therapy, she claims, has been a lack of safe and effective delivery mechanisms for RNAi molecules.
“Nanotechnology could be used to address this.” “The combination of employing nano curcumin to encapsulate the medicine allows for improved targeting and uptake by malignant cells at the tumour site,” claimed the Thiruvananthapuram native. Dr Lekha’s proposed bio drug is both non-toxic and biocompatible. The findings show that a nano-RNAi drug formulation effectively regresses tumours by effectively shutting down target genes.
The pre-clinical research was carried out on mice models. “We could see that when the medication was administered, the mice’s lifetime increased by one-fourth.” When compared to humans, this provides good longevity. “A one-fourth increase in a lifetime would equate to an increase of 20 to 25 years for humans,” explains Dr Lekha. Human clinical studies are the next stage.


Leave a Reply

Your email address will not be published. Required fields are marked *